Journal
CELL REPORTS
Volume 32, Issue 3, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2020.107918
Keywords
-
Categories
Funding
- National Major Science and Technology Projects of China [2018ZX10301403]
- National Key Research and Development Program of China [2016YFA0101800, 2018YFA0108700]
- National Natural Science Foundation of China [31925010]
- Shanghai Municipal Science and Technology Major Project [2017SHZDZX01]
- Zhejiang University Special Scientific Research Fund for COVID-19 Prevention and Control [2020XGZX023]
- Shanghai Pujiang Program [19PJ1409100]
- Natural Science Foundation of China [81761128007]
- Shanghai Committee of Science and Technology [18DZ2293000]
Ask authors/readers for more resources
Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC50 below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC50 within 10 nM, and the best one, 414-1, with IC50 of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available